Welcome to our dedicated page for Amedisys SEC filings (Ticker: AMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Complex Medicare reimbursement tables, shifting hospice regulations, and acquisition footnotes can make Amedisys, Inc. (NASDAQ: AMED) filings feel like a maze. If you have ever asked, 鈥淗ow do I locate the labor-cost breakout in Amedisys鈥� annual report 10-K?鈥� or 鈥淲here are Amedisys insider trading Form 4 transactions listed in real time?鈥�, this page is built for you.
Stock Titan鈥檚 AI-powered engine turns every AMED disclosure鈥�10-K, 10-Q, 8-K, DEF 14A, S-8, and more鈥攊nto clear, searchable insights. Our algorithms read the footnotes so you can quickly:
- Track clinician head-count trends inside the latest Amedisys quarterly earnings report 10-Q filing.
- Review hospice cap exposure highlighted in the Amedisys annual report 10-K simplified.
- Receive instant alerts for every Amedisys Form 4 insider transactions real-time, including executive stock sales ahead of rate-setting announcements.
- See board-level pay packages with a single click in the Amedisys proxy statement executive compensation.
Each document includes an AI summary that explains material events, from acquisition-related goodwill in an 8-K to segment margin shifts buried deep in MD&A. No more skimming hundreds of pages鈥攐ur expert analysis highlights reimbursement changes, patient-census data, and cash-flow details investors use to benchmark post-acute providers.
Whether you鈥檙e comparing home-health operators or trying to understand 鈥淎medisys insider trading Form 4 transactions鈥�, this hub delivers every filing the moment it hits EDGAR, already decoded. Spend your time making decisions, not finding disclosures.
Q2 2025 snapshot: Net service revenue rose 5.2% to $621.9 m, but operating income slid 12.7% to $45.6 m as merger-related expenses jumped to $26.3 m. Net income attributable to Amedisys fell 13% to $28.1 m, driving diluted EPS down to $0.84 from $0.98 a year ago.
Year-to-date: First-half revenue climbed 4.7% to $1.22 bn. A $48.1 m gain from the Medalogix equity rollover propelled net income 92% higher to $89.1 m (EPS $2.68). Operating cash flow improved to $63.5 m, lifting cash to $337.3 m. Debt consists mainly of a $338.1 m term loan at 5.9%; the $550 m revolver remains undrawn, and total equity increased to $1.27 bn.
Balance-sheet & liquidity: Current ratio strengthened (assets $662 m vs liabilities $488 m). No covenant breaches reported after extending the credit facility maturity to 30 Jul 2027.
Strategic & regulatory: The $101-per-share merger with UnitedHealth is contested by the DOJ; trial is pencilled in for 27 Oct 2025 and the outside date extended to 31 Dec 2025. Planned divestitures to BrightSpring and Pennant depend on DOJ approval. Management highlights 68% Medicare concentration, ongoing labor tightness and audit exposure as key risks.
Crown Holdings (CCK) reported Q2-25 results that showed moderate top-line growth and sharply higher profitability. Net sales rose 3.6% YoY to $3.15 bn and operating income improved 3.2% to $391 m despite $47 m of restructuring/other charges. Net income attributable to Crown increased 4% to $181 m; diluted EPS expanded 7.6% to $1.56 on a 3% lower share count following $209 m of buybacks.
First-half trends were stronger. Six-month revenue grew 3.6% to $6.04 bn while EPS jumped 59% to $3.21, aided by lower interest expense (-10%) and higher segment income (+11%). Operating cash flow reached $463 m (+35%), easily covering reduced capex of $89 m and funding dividends ($60 m) and repurchases.
Balance-sheet quality improved. Long-term debt fell $440 m to $5.62 bn after redeeming $875 m of 4.75% notes (partly replaced with a new $700 m 5.875% 2033 issue). Net leverage benefits from higher cash ($936 m) and stronger EBITDA. However, current maturities surged to $671 m as 2026 notes move inside twelve months.
Notable items. 鈥� $11 m asbestos reserve tied to an adverse California verdict; total asbestos accrual now $189 m. 鈥� FX translation gains lifted OCI but net investment hedge losses of $98 m offset. 鈥� Segment income rose in Americas and Europe but slipped in Asia-Pacific. 鈥� Supplier-finance obligations stay high at $883 m.
Outlook. Management continues to emphasize long-term beverage-can demand growth, disciplined capex, debt pay-down and the $2.0 bn buyback authorization through 2027.
On 07/29/2025 Orrstown Financial Services (ORRF) filed a Form 4 for EVP & Chief Experience Officer Michael Jaeger. The executive sold 642 common shares on 07/28/2025 at $34.25 (transaction code 鈥淪鈥�). After the sale, Jaeger directly owns 745 unrestricted shares and 4,198 restricted shares that vest over the next three years.
No derivative securities were involved and no purchases were reported. The disposition reduced Jaeger鈥檚 freely tradable stake by roughly 46 % (642 of 1,387 previously held). No other insiders are covered in this filing.
Amedisys Inc. (AMED) 鈥� Form 4 filing overview
Director Bruce D. Perkins reported one transaction dated 07/01/2025. Using transaction code 鈥淕鈥� (gift), Perkins transferred 105 shares of Amedisys common stock at a stated price of $0. Following the gift, the director鈥檚 direct beneficial ownership stands at 23,992 shares.
The filing does not disclose any derivative security activity and contains no additional explanatory remarks beyond the standard signature block.
- Size of transaction: ~0.4 % of the director鈥檚 post-transaction holdings
- Insider relationship: Director (non-executive)
- Ownership form: Direct
No other material financial data, earnings information, or strategic commentary is included in this short Form 4.
Compass Minerals International, Inc. (CMP) filed a Form 4/A to correct a duplicate insider filing made on 1 July 2025. The amendment re-affirms that Director Joseph E. Reece received 2,209 deferred stock units on 30 June 2025 at a grant price of $0 as part of standard board compensation. Following the grant, Reece now directly owns 65,755 CMP shares and indirectly holds 21,000 shares via a trust. No derivative securities were involved and there are no changes to the underlying transaction details; the sole purpose of the Form 4/A is to replace an inadvertently duplicated submission.
The disclosure is routine, reflects non-cash compensation, and does not signal any strategic shift or financial impact for CMP.
Rubrik, Inc. (RBRK) has filed a Form 144 indicating that an affiliate intends to sell up to 16,984 Class A shares through Merrill Lynch on or after 06/30/2025. The proposed transaction has an aggregate market value of $1.52 million and represents roughly 0.014% of the company鈥檚 123.6 million shares outstanding, suggesting limited market impact. The shares were originally acquired in a private placement on 01/27/2014 for cash. The filing also lists prior sales over the past three months by related Lightspeed entities totaling 46,269 shares for $3.71 million in gross proceeds. The signatory attests that no undisclosed material adverse information is known.
FAQ
What is the current stock price of Amedisys (AMED)?
What is the market cap of Amedisys (AMED)?
What core services does Amedisys Inc provide?
How does Amedisys ensure personalized care for its patients?
What differentiates Amedisys from traditional healthcare providers?
How does Amedisys coordinate care with other healthcare providers?
What role does technology play in Amedisys' care delivery model?
How does the high acuity care segment operate?
Can Amedisys' care services help reduce hospital readmissions?
What is the market significance of Amedisys Inc in the healthcare industry?
